Fidelity Investments’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $186M | Buy |
17,069,149
+272,170
| +2% | +$3.4M | 0.01% | 893 |
|
|
2025
Q4 | $217M | Buy |
16,796,979
+27,101
| +0.2% | +$348K | 0.01% | 838 |
|
|
2025
Q3 | $217M | Buy |
16,769,878
+47,123
| +0.3% | +$630K | 0.01% | 807 |
|
|
2025
Q2 | $298M | Buy |
16,722,755
+235,477
| +1% | +$4.1M | 0.02% | 667 |
|
|
2025
Q1 | $294M | Buy |
16,487,278
+257,139
| +2% | +$5.84M | 0.02% | 662 |
|
|
2024
Q4 | $484M | Sell |
16,230,139
-1,869
| -0% | -$39.6K | 0.03% | 481 |
|
|
2024
Q3 | $254M | Buy |
16,232,008
+90,422
| +0.6% | +$1.64M | 0.02% | 740 |
|
|
2024
Q2 | $277M | Buy |
16,141,586
+77,618
| +0.5% | +$1.37M | 0.02% | 665 |
|
|
2024
Q1 | $251M | Buy |
16,063,968
+101,201
| +0.6% | +$1.49M | 0.02% | 711 |
|
|
2023
Q4 | $238M | Buy |
15,962,767
+3,219
| +0% | +$43.1K | 0.02% | 680 |
|
|
2023
Q3 | $258M | Buy |
15,959,548
+29,525
| +0.2% | +$851K | 0.02% | 604 |
|
|
2023
Q2 | $661M | Buy |
15,930,023
+124,806
| +0.8% | +$7.75M | 0.06% | 332 |
|
|
2023
Q1 | $951M | Buy |
15,805,217
+68,538
| +0.4% | +$5.48M | 0.09% | 216 |
|
|
2022
Q4 | $1.15B | Buy |
15,736,679
+296,571
| +2% | +$22.3M | 0.11% | 165 |
|
|
2022
Q3 | $1.17B | Buy |
15,440,108
+2,898,102
| +23% | +$226M | 0.12% | 146 |
|
|
2022
Q2 | $872M | Buy |
12,542,006
+1,812,136
| +17% | +$137M | 0.09% | 213 |
|
|
2022
Q1 | $889M | Buy |
10,729,870
+2,926,367
| +38% | +$216M | 0.07% | 264 |
|
|
2021
Q4 | $586M | Sell |
7,803,503
-471,384
| -6% | -$47.3M | 0.04% | 402 |
|
|
2021
Q3 | $961M | Sell |
8,274,887
-1,344,248
| -14% | -$203M | 0.08% | 240 |
|
|
2021
Q2 | $2.13B | Buy |
9,619,135
+530,696
| +6% | +$103M | 0.17% | 97 |
|
|
2021
Q1 | $1.2B | Sell |
9,088,439
-539,115
| -6% | -$85.3M | 0.1% | 188 |
|
|
2020
Q4 | $1.67B | Sell |
9,627,554
-328,806
| -3% | -$45M | 0.15% | 121 |
|
|
2020
Q3 | $1.11B | Sell |
9,956,360
-482,174
| -5% | -$38.6M | 0.11% | 162 |
|
|
2020
Q2 | $619M | Sell |
10,438,534
-1,400,625
| -12% | -$92.1M | 0.07% | 257 |
|
|
2020
Q1 | $797M | Sell |
11,839,159
-340,270
| -3% | -$26.9M | 0.11% | 170 |
|
|
2019
Q4 | $1.03B | Buy |
12,179,429
+274,398
| +2% | +$22.1M | 0.11% | 171 |
|
|
2019
Q3 | $890M | Buy |
11,905,031
+1,601,733
| +16% | +$128M | 0.11% | 187 |
|
|
2019
Q2 | $651M | Sell |
10,303,298
-134,390
| -1% | -$6.81M | 0.08% | 255 |
|
|
2019
Q1 | $503M | Sell |
10,437,688
-752,693
| -7% | -$36.2M | 0.06% | 308 |
|
|
2018
Q4 | $375M | Buy |
11,190,381
+345,135
| +3% | +$12.6M | 0.05% | 363 |
|
|
2018
Q3 | $568M | Buy |
10,845,246
+2,983,125
| +38% | +$119M | 0.06% | 287 |
|
|
2018
Q2 | $246M | Buy |
7,862,121
+881,776
| +13% | +$24.5M | 0.03% | 591 |
|
|
2018
Q1 | $152M | Sell |
6,980,345
-1,085,854
| -13% | -$23.4M | 0.02% | 795 |
|
|
2017
Q4 | $163M | Buy |
8,066,199
+269,264
| +3% | +$5.19M | 0.02% | 773 |
|
|
2017
Q3 | $155M | Buy |
7,796,935
+908,815
| +13% | +$17.9M | 0.02% | 780 |
|
|
2017
Q2 | $119M | Buy |
6,888,120
+2,309,559
| +50% | +$29.8M | 0.01% | 898 |
|
|
2017
Q1 | $37.1M | Sell |
4,578,561
-311,100
| -6% | -$2.25M | ﹤0.01% | 1453 |
|
|
2016
Q4 | $38.4M | Buy |
4,889,661
+10,691
| +0.2% | +$86K | 0.01% | 1415 |
|
|
2016
Q3 | $41.7M | Sell |
4,878,970
-117,051
| -2% | -$1.07M | 0.01% | 1373 |
|
|
2016
Q2 | $58.3M | Sell |
4,996,021
-529,200
| -10% | -$6.63M | 0.01% | 1208 |
|
|
2016
Q1 | $80M | Buy |
5,525,221
+347,818
| +7% | +$4.99M | 0.01% | 1069 |
|
|
2015
Q4 | $116M | Buy |
+5,177,403
| New | +$124M | 0.02% | 902 |
|
Other funds holding NVCR
SCM
VPM
VCM
QCM
Fidelity Investments's NVCR Position: Q1 2026 in Review
Fidelity Investments increased its NovoCure (NVCR) stake by 1.6% in Q1 2026, buying an estimated $3.4M and bringing the position to 17,069,149 shares worth $186M. The position accounts for 0.01% of the portfolio, ranked #893.
Fidelity Investments first reported a position in NVCR in Q4 2015 and has held it in 42 quarters since. The position peaked at $2.13B in Q2 2021. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.
- Fidelity Investments held 17,069,149 shares of NovoCure worth $186M as of Q1 2026.
- Fidelity Investments bought 272,170 NovoCure shares in Q1 2026, an estimated $3.4M.
- NovoCure made up 0.01% of Fidelity Investments's portfolio in Q1 2026, its #893 holding.
- Fidelity Investments first reported a position in NovoCure in Q4 2015 and has held it in 42 quarters since.
- Fidelity Investments's NovoCure position peaked at $2.13B in Q2 2021.
- 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.
Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.